Werewolf Therapeutics stock rises as HC Wainwright places Buy rating over pipeline tech
seekingalpha.com
finance
2022-06-02 16:16:24

Fabrice Cabaud/iStock via Getty Images Werewolf Therapeutics (NASDAQ:HOWL) stock rose ~7% June 2 after H.C. Wainwright assumes coverage of the company with a Buy rating and $20 price target. Analyst Andres Maldonado noted that Werewolf's Predator protein engineering technology aims to mimic natural cytokine activity while improving the therapeutic window and the systemic toxicities linked with such class of therapies. He added that the company's pipeline technology could attract further collaborations.
